The Phase 3 clinical trial NCT06616961, investigating semaglutide for weight loss in overweight or obese adults in Bangladesh, reached its primary completion date on 2025-02-28. This trial aims to evaluate the efficacy and safety of semaglutide in this specific population.
Background
The trial, titled "Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus," is designed to assess the potential of semaglutide to aid weight loss and its safety profile in adults in Bangladesh who are overweight or obese, with or without Type 2 Diabetes Mellitus.
Trial design
The study, identified as NCT06616961, is a Phase 3 clinical trial with an estimated enrollment of 480 participants. It focuses on adults in Bangladesh diagnosed with obesity or Type 2 Diabetes Mellitus (T2DM). Participants are planned to receive a weekly injection of semaglutide (2.4 mg) for 26 weeks, alongside lifestyle changes including diet and physical activity. The trial aims to determine if semaglutide helps participants lose weight after 26 weeks and to observe changes in health measures like blood sugar and quality of life.
What this means
The primary completion of this Phase 3 trial indicates that the final data collection for the primary outcome measure is expected to be finished by February 28, 2025. Once the trial is fully completed and results are analyzed, the findings will provide important insights into the efficacy and safety of semaglutide for weight management in the Bangladeshi population, potentially informing future treatment guidelines and availability in the region.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The primary completion date for study NCT06616961, titled "Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus," is listed as 2025-02-28 on clinicaltrials.gov.